ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for…
Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseases Korsana Biosciences, Inc. a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced its emergence…
Flashpoint Therapeutics Announces Major Publication on Novel HPV Cancer Vaccine Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicines, today announced a major, peer-reviewed publication demonstrating the power of its Spherical Nucleic Acid (SNA) platform in immuno-oncology.…
Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement Twist Bioscience Corporation a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. (“Invenra”), a company that has developed platform technologies…
Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program Newron Pharmaceuticals S.p.A. a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that…
Worldwide Clinical Trials Completes Acquisition of Catalyst Clinical Research Worldwide Clinical Trials a global contract research organization (CRO), has completed its acquisition of Catalyst Clinical Research, LCC (“Catalyst”) – a specialized oncology CRO and scalable functional service provider (FSP). This strategic transaction creates a combined organization…
Australian Breast Cancer Innovators Close $27M Private Funding Round OncoRes Medical today announced it has closed an AUD $27M private funding round (‘the Funding round’) to progress clinical development and regulatory milestones for its Quantitative Micro-Elastography (QME) Imaging System, Elora™.…
Owlet Announces Strategic DME Partnership with PromptCare to Expand Distribution of Pediatric Pulse Oximeter, BabySat® Owlet, Inc. the pioneer of smart infant monitoring, today announced a new strategic partnership with PromptCare, a leading national respiratory services and durable medical equipment (DME)…
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU)…
Dr. Joseph Chang Launches Update to Bestselling Book “The Aging Myth” With 15 More Years of Breakthrough Research on Cellular Wellness Nu Skin Enterprises Inc. today announced the relaunch of “The Aging Myth: Unlocking the Mysteries of Looking and Feeling…
Pfizer’s Monthly Ultra-Long-Acting Injectable GLP-1 RA Demonstrates Sustained and Significant Weight Loss in Phase 2b Trial Pfizer Inc. today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1 receptor…
Exelixis Announces FDA Acceptance of New Drug Application for Zanzalintinib Combined with Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Exelixis, Inc. today announced that its New Drug Application (NDA) for zanzalintinib, in combination with atezolizumab (Tecentriq®), has been accepted for…